The enactment of the FDA Good Laboratory Practices (GLPs) into law by the FDA has led to major changes throughout industrial toxicology programs. One major addition to toxicology studies, as specified in the GLPs, includes the requirement of a quality assurance (QA) program. Initially, the role of QA was that of monitor or auditor. This role has expanded in a practical sense, however, to include a working knowledge of regulatory affairs and principles of toxicology. Since 1978, new GLPs and test standards have been issued by several countries, including the United States. The requirements and guidelines set forth by various countries, while similar in content, are different in their specific details. The development of comprehensive, scientifically sound protocols to meet these new requirements necessitates a continual assessment of the regulations in effect in the countries where registration is sought. Thus, the role of QA has expanded to include the assessment of guidelines and protocols to assure that toxicology studies conducted to support registration are in compliance with these guidelines. N recent years, toxicological research has shown dynamic growth. Improved test methods have Address reprint requests to:
I been developed that key in on major toxicity parameters, such as cancer, teratology, mutagenicity, reproduction, and pharmacodynamics. With this productive growth in toxicological research, regulatory impact on and control of the conduct of toxicological tests have been significant. For example, Congress has enacted an amended Federal Insecticide Rodenticide and Fungicide Act (FIFRA) for the registration of pesticide products. FIFRA requires extensive testing, including cancer assays, chronic toxicity, and mutagenic, teratogenic, and reproductive studies. In addition, a number of acute and subchronic studies are conducted to assess various other toxicological parameters. Similarly, the Food Drug and Cosmetic Act (FDCA) requires extensive toxicity testing for pharmaceutical products, food additives, and animal drug products.
In order to cope with and provide control for the extensive variety of toxicity tests required by FDCA, the Food and Drug Administration (FDA) has issued Good Laboratory Practice (GLP) regulations. The FDA/GLPs essentially control the conduct of toxicological tests by providing specifications, including protocol content, the handling of test substances and animals, the conduct of the study, and the content of the final report.") In a similar manner, the Environmental Protection Agency (EPA) has issued "Guidelines for Registering Pesticides in the United States,''(2) which provide guidance to registrants of pesticide products on protocol development, test methodology, and other critical and essential criteria to assess the toxicity of a pesticide. Associated with the Guidelines, EPA has issued a proposed rule ' ROYAL that specifies the kinds of data and information that must be submitted to EPA to support the registration of each pesticide under FIFRA.3 EPA works in concert with FDA to review requirements and studies conducted under the Guidelines and FIFRA proposed Part 158.
Included in the GLPs is the requirement for a quality assurance unit. This unit is responsible for monitoring studies to ensure that tests are being conducted according to GLP requirements and that the protocol and the facility's standard operating procedures also meet those requirements. A major difference between quality control and quality assurance is centered in these specifications. While quality control does include monitoring the quality of the tests being conducted, it is an internal control; quality assurance must, in addition, ensure that the internal controls conform to government standards. While this was and still is the major thrust of the quality assurance unit, the role of quality assurance is changing. New scientific technology and regulatory reform are demanding that the quality assurance unit become increasingly knowledgeable in regulatory affairs and in the basic principles of toxicology. Guidelines and testing requirements are continually being changed. New guidelines and test standards have recently been written by the Organization for Economic and Cooperative Development (OECD), Japan, in addition to those of the United States. While similar requirements are contained in all of these standards, subtle differences do exist. These differences include the number of animals in each dose group, the use of satellite groups, specific examinations and parameters to be measured, including ophthalmics, clinical chemistry, hematology measurements, and urinalysis, and type of statistical tests used to analyze the data. For a large corporation interested in obtaining multinational registration, it is important to develop a protocol that simultaneously incorporates the requirements from many countries. This requires maintaining good scientific judgment while continually assessing recent test standards within the toxicology laboratory. Because of its unique position, this responsibility has become an another facet of the quality assurance unit. Regulatory change affecting protocol design can be found in many of the standard toxicology protocols, in addition to those of environmental field testing. Recent changes can be found in test standards affecting 2-year rodent studies, teratology studies, and inhalation studies, along with a new requirement for GLP monitoring of environmental field testing under OECD and the Toxic Substance and Control Act (TSCA). With this in mind, the importance of planning a comprehensive approach to assessing thrt toxic properties of a compound and its potential registration become obvious. In writing a protocol, it is important at the outset to have a clear understanding of where registration is sought. This is necessary so that an assessment can be made of the regulatory requirements in effect in that country or countries. Major amendments to a protocol, involving animal number and/or test measurements after a study has been initiated, are difficult and potentially troublesome.
Once a study is initiated, the role of quality assurance is not only that of a monitor but also that of liaison and troubleshooter. In this capacity the quality assurance unit interacts with the scientific staff, company management, and regulatory personnel. In a monitoring role, studies are reviewed for data-handling procedures, equipment maintenance, and the insurance that technical procedures are carried out as described in the facility's standard operating procedures. No matter how detailed the planning stage of the study was, during the in-life phase of a study, problems must be anticipated. Problem solving very often involves the coordination of events or the resolution of new and conflicting regulations. This can involve documentation and handling of archived specimens, analysis of test substances, or handling of animals; therefore, the solution involves the quality assurance unit. Often, policies must be established to document laboratory operation and regulatory interpretations beyond those described in the facility's standard operating procedures.
Remembering that guidelines are established to be flexible, a good example of where laboratory policy should be established is provided by acute inhalation protocols. EPA test standards for acute inhalation studies specify as a maximum test limit a 5 mg/L exposure concentration or, alternatively, the highest attainable level, for 4 hours. If no mortality is encountered after a 14-day observation period, no further testing is required. If mortality occurs, an LC,, for that chemical must be determined, even if that LC,, exceeds the 5 mg/L test limit.(4) Depending on the state of the art used at the individual laboratory, the "highest attainable level" of a specific chemical can vary. This could PRODUCT REGISTRATION AND REGULATORY CHANGE place one laboratory in a position of having to determine an LCso of a chemical at great expense and time, while another laboratory might not.
While some requirements of this type have remained relatively stable for the past few years, others have not. Initially, proposed test standards for teratology studies conducted for EPA required three dose groups and a concurrent vehicle control, in addition to data obtained from a positive or historical control group. The highest dose had to induce some fetal or maternal toxicity yet not more than 10% maternal fatality, while the low dose had to establish a no observable effect level.(') More recently, EPA has established an upper limit of 1000 mg/kg for teratology studies. If no evidence of embryo toxicity or teratology is encountered in preliminary studies showing definite maternal toxicity conducted at this limit, no further testing may be necessary. 14) Changes of this type clearly affect the design of study protocols. Likewise, they affect the type of data collected t o support the registration of a product. In assessing the overall trends of regulatory change in EPA, one can see an attempt to make requirements more flexible and scientifically meaningful while still maintaining the same rigorous standards set forth in the initial proposed test standards.
At the conclusion of a study conducted in an industrial toxicology laboratory, the final report is submitted to the quality assurance unit for audit. GLPs specify that studies must be audited to insure that the conclusions of the report are accurate interpretations of the collected data. Throughout the audit, two basic questions must be kept in mind: (1) does the report meet all specifications of the GLPs and the protocol? (2) Is the report scientifically sound? Procedures used in conducting a report audit, including the number of data points to be checked, methods of randomizing those data points, and editing the text, vary with the type of study and the quality assurance unit conducting the audit. However, the purpose of the audit remains the same: to determine the accuracy of the final report. Because of the complex nature and variety of studies being conducted, it becomes mandatory that the quality assurance unit have a good scientific knowledge of the basic principles of toxicology. In this context, the quality assurance unit must be free to comment on the clarity of the scientific interpretation in addition to reviewing the data. Finally and most importantly, the quality assurance unit must ask if the report, or package, is complete. Are all the raw data present? Have all requirements been met? Is the text clear? This must be established prior to releasing the report and issuing the quality assurance statement.
Throughout the progression of a study, it is important that every quality assurance unit develop a mode of operation-a mode of operation that fulfills the responsibilities placed upon it by the company to insure compliance with GLPs, while guarding against a rigidity that can lead to stagnation of scientific creativity and expertise. This requires tact on the part of the quality assurance unit. It also necessitates support by management and an acknowledgment of the role that quality assurance plays-its interactions with registration and regulatory groups, as well as those of the toxicology laboratory to which it is connected. In this context it is legitimate to ask if the presence of quality assurance reduces productivity. The requirements and responsibilities placed on the quality assurance unit are great. On entering any laboratory, the quality assurance unit can represent an authoritative force that can be unnecessarily intimidating and counterproductive. As an alternative, it can lead to an opportunity to work out problems to mutual benefit. If reagent storage and expiration dates are not routinely examined, experiments can be lost or erroneous results can be produced. If inadequate protocols are written, studies may have to be repeated, inaccurate interpretations may be made, and registration may be delayed.
While the nature of research conducted in government, academic, and industrial toxicology laboratories traditionally differ in approach, the goal remains the same, i.e., an assessment of toxic substances and their effects on living organisms. It can be foreseen that universities could obtain substantial financial support by receiving contracts from industry to conduct toxicity assessment studies directly regulated by GLPs. These studies would require the same rigid standards specified by GLPs under which industrial studies are currently being conducted. This would include protocol design, standard operating procedures, and the establishment of a quality assurance monitoring program. Some aspects of government or academic basic research not directly controlled by GLPs could provide data on a compound regulated in another area. By providing a consistant method for data ROYAL collection, direct comparisons could be made and the overall assessment of that compound could be enhanced. Already, the National Toxicology Program is establishing a monitoring concept based on GLP requirements. Current trends seen in regulatory affairs throughout the world suggest that the effects of the GLPs will increase.
With these ideas in mind, one of the major roles of the quality assurance unit is to inform scientists of the regulatory requirements affecting their work. Recent regulatory change has been dynamic. This has affected academic and government programs, as well as those of industrial research. One can foresee that the effects of these changes will increase, thus affording a stage for greater interaction among these groups. One major result of the enactment of the FDA GLPs was the requirement for a quality assurance unit. This requirement initially mandated the role of quality assurance to be that of a monitor. With increasing regulatory control seen throughout the world, the involvement of quality assurance in toxicology today has expanded into areas of regulatory affairs, in toxicity evaluation, and most recently in environmental field testing. In light of the rapid developments that have taken place, an understanding of the evolving process of produce registration and regulatory change and the role played by quality assurance has been the purpose of this presentation. In this context, I have discussed the effects of increased regulatory control throughout the world on industrial toxicity testing, the effects of GLPs and test standards, their potential effects on government and academic laboratories in addition to those of industrial toxicology programs, changing guidelines and protocols, the need for planning overall toxicity assessment of a compound, the responsibilities of the study director and the quality assurance unit, and their roles in the process of the registration of a compound. This conference has been the first major opportunity for quality assurance personnel to discuss their impact on toxicology outside of their own professional organizations. With the changing role of the quality assurance unit, it is hoped that it marks only a beginning.
